We are live on ! Find out more
NVS icon

Novartis

1,400 hedge funds and large institutions have $17.2B invested in Novartis in 2025 Q3 according to their latest regulatory filings, with 115 funds opening new positions, 476 increasing their positions, 481 reducing their positions, and 74 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 115 | Existing positions closed: 74

6% more capital invested

Capital invested by funds: $16.2B → $17.2B (+$990M)

1% more funds holding

Funds holding: 1,3831,400 (+17)

0.02% more ownership

Funds ownership: 6.32%6.34% (+0.02%)

1% less repeat investments, than reductions

Existing positions increased: 476 | Existing positions reduced: 481

34% less call options, than puts

Call options by funds: $261M | Put options by funds: $398M

35% less funds holding in top 10

Funds holding in top 10: 1711 (-6)

Holders
1,400
Holders Change
+17
Holders Change %
+1.23%
% of All Funds
18.37%
Holding in Top 10
11
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-35.29%
% of All Funds
0.14%
New
115
Increased
476
Reduced
481
Closed
74
Calls
$261M
Puts
$398M
Net Calls
-$136M
Net Calls Change
-$74.7M
Name Holding Trade Value Shares
Change
Change in
Stake
HF
101
HRT Financial
New York
$17.8M +$12.3M +100,879 +266%
FFIC
102
First Fiduciary Investment Counsel
Ohio
$17.5M -$43.1K -353 -0.3%
Mercer Global Advisors
103
Mercer Global Advisors
Colorado
$17.5M +$179K +1,465 +1%
CIM
104
Coleford Investment Management
Canada
$17.4M -$329K -2,700 -2%
AQR Capital Management
105
AQR Capital Management
Connecticut
$17.4M +$7.62M +62,447 +85%
WIC
106
Wilkins Investment Counsel
Massachusetts
$17.2M -$664K -5,443 -4%
GHA
107
GW Henssler & Associates
Georgia
$17.1M -$236K -1,938 -1%
PL
108
Parkwood LLC
Ohio
$17.1M -$11.5M -94,334 -42%
VPIM
109
Vanguard Personalized Indexing Management
California
$17M +$845K +6,924 +6%
ISL
110
Ingalls & Snyder LLC
New York
$16.9M -$19.5K -160 -0.1%
QCM
111
QRG Capital Management
Illinois
$16.1M -$8.07M -66,101 -34%
BCAM
112
Boston Common Asset Management
Massachusetts
$15.9M -$1.75M -14,347 -10%
Neuberger Berman Group
113
Neuberger Berman Group
New York
$15.6M +$786K +6,440 +6%
CWP
114
Capital Wealth Planning
Florida
$15.2M +$3.48M +28,520 +32%
P
115
&Partners
Tennessee
$15.1M +$1.23M +10,081 +9%
TAM
116
Tocqueville Asset Management
New York
$14.9M -$50.3K -412 -0.4%
EIA
117
Edgemoor Investment Advisors
Maryland
$14M -$207K -1,699 -2%
Allspring Global Investments
118
Allspring Global Investments
North Carolina
$13.9M -$539K -4,419 -4%
CAM
119
Cresset Asset Management
Illinois
$13.9M +$417K +3,420 +3%
Pathstone Holdings
120
Pathstone Holdings
New Jersey
$13.7M +$495K +4,060 +4%
Jane Street
121
Jane Street
New York
$13.6M +$7.11M +58,237 +121%
New York State Common Retirement Fund
122
New York State Common Retirement Fund
New York
$13.6M +$458K +3,753 +4%
Rockefeller Capital Management
123
Rockefeller Capital Management
New York
$13.2M +$602K +4,936 +5%
RWM
124
Ritholtz Wealth Management
New York
$13M +$103K +841 +0.8%
Massachusetts Financial Services
125
Massachusetts Financial Services
Massachusetts
$12.7M +$3.04M +24,897 +33%

NVS Hedge Fund Activity: Q3 2025 in Review

1,400 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2025, worth a combined $17.2B — up 6.1% from $16.2B a quarter earlier.

Buyers outnumbered sellers: 115 funds opened new NVS positions and 74 closed out — a net gain of 41 holders — while 476 added to existing stakes and 481 trimmed.

The largest buyer was GQG Partners, adding an estimated $268M. The largest seller was Wellington Management Group, cutting an estimated $134M.

  • 1,400 institutional investors held Novartis (NVS) as of Q3 2025, up from 1,383 in Q2 2025.
  • Funds reported $17.2B of Novartis stock for Q3 2025, up 6.1% quarter-over-quarter.
  • 115 funds opened new Novartis positions in Q3 2025 and 74 closed out, a net change of +41 holders.
  • The largest Novartis buyer in Q3 2025 was GQG Partners, an estimated $268M added.
  • The largest Novartis seller in Q3 2025 was Wellington Management Group, an estimated $134M sold.

Based on aggregated 13F filings for Q3 2025.